EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria

Nicholas H Chia iD, Andrew McKeon iD, Marinos C Dalakas iD, Eoin P Flanagan, James H Bower, Bryan T Klassen, Divyanshu Dubey iD, Nicholas L Zalewski, Dustin Duffy, Sean J Pittock iD, Anastasia Zekeridou iD

Annals of Clinical and Translational Neurology · 2023-07 · 10 (7) · 1083-1094

DOI: 10.1002/acn3.51791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 22.05.2023. Verfasst von Nicholas H Chia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Autoantibodies, Stiff-Person Syndrome. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stiff person spectrum disorder (SPSD) is heterogeneous, and accurate diagnosis can be challenging.

Methods

Patients referred for diagnosis/suspicion of SPSD at the Mayo Autoimmune Neurology Clinic from July 01, 2016, to June 30, 2021, were retrospectively identified. SPSD diagnosis was defined as clinical SPSD manifestations confirmed by an autoimmune neurologist and seropositivity for high‐titer GAD65‐IgG (>20.0 nmol/L), glycine‐receptor‐IgG or amphiphysin‐IgG, and/or confirmatory electrodiagnostic studies (essential if seronegative). Clinical presentation, examination, and ancillary testing were compared to differentiate SPSD from non‐SPSD.

Results

Of 173 cases, 48 (28%) were diagnosed with SPSD and 125 (72%) with non‐SPSD. Most SPSD were seropositive (41/48: GAD65‐IgG 28/41, glycine‐receptor‐IgG 12/41, amphiphysin‐IgG 2/41). Pain syndromes or functional neurologic disorder were the most common non‐SPSD diagnoses (81/125, 65%). SPSD patients more commonly reported exaggerated startle (81% vs. 56%, p = 0.02), unexplained falls (76% vs. 46%, p = 0.001), and other associated autoimmunity (50% vs. 27%, p = 0.005). SPSD more often had hypertonia (60% vs. 24%, p < 0.001), hyperreflexia (71% vs. 43%, p = 0.001), and lumbar hyperlordosis (67% vs. 9%, p < 0.001) and less likely functional neurologic signs (6% vs. 33%, p = 0.001). SPSD patients more frequently had electrodiagnostic abnormalities (74% vs. 17%, p < 0.001), and at least moderate symptomatic improvement with benzodiazepines (51% vs. 16%, p < 0.001) or immunotherapy (45% vs. 13% p < 0.001). Only 4/78 non‐SPSD patients who received immunotherapy had alternative neurologic autoimmunity.

Interpretation

Misdiagnosis was threefold more common than confirmed SPSD. Functional or non‐neurologic disorders accounted for most misdiagnoses. Clinical and ancillary testing factors can reduce misdiagnosis and exposure to unnecessary treatments. SPSD diagnostic criteria are suggested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesStiff-Person SyndromeHumansRetrospective StudiesReceptors, GlycineDiagnostic ErrorsImmunoglobulin GGlycine

Substanzen

AutoantibodiesReceptors, GlycineImmunoglobulin GGlycine

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Center of MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Neuroimmunology Unit, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.

ORCID-Profile: Nicholas H Chia, Andrew McKeon, Marinos C Dalakas, Divyanshu Dubey, Sean J Pittock, Anastasia Zekeridou

Förderung

  • NINDS NIH HHS
  • National Institutes of Health

Zitieren

APA

Chia, N. H., McKeon, A., Dalakas, M. C., Flanagan, E. P., Bower, J. H., Klassen, B. T., Dubey, D., Zalewski, N. L., Duffy, D., Pittock, S. J., & Zekeridou, A. (2023). Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Annals of Clinical and Translational Neurology, 10(7), 1083-1094. https://doi.org/10.1002/acn3.51791

Vancouver

Chia NH, McKeon A, Dalakas MC, Flanagan EP, Bower JH, Klassen BT, et al. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Annals of Clinical and Translational Neurology. 2023;10(7):1083-1094. doi:10.1002/acn3.51791

BibTeX
@article{Chia2023,
  author = {Chia, Nicholas H and McKeon, Andrew and Dalakas, Marinos C and Flanagan, Eoin P and Bower, James H and Klassen, Bryan T and Dubey, Divyanshu and Zalewski, Nicholas L and Duffy, Dustin and Pittock, Sean J and Zekeridou, Anastasia},
  title = {Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2023},
  volume = {10},
  number = {7},
  pages = {1083--1094},
  doi = {10.1002/acn3.51791}
}
Kostenlos starten →